Pilkington V, et al. Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP (n = 15,678). Abstract O143, HIV/Drug Therapy Glasgow 2018.
Tafenoquine plus dihydroartemisinine-piperaquine voor Plasmodium vivax-malaria?
jan 2024 | Parasitaire infecties